nursesrevision@gmail.com

HIV AND PREGNANCY

HIV (Human Immunodeficiency Virus) is a virus that attacks the body\’s immune system, specifically the CD4 cells (T cells), which are important for immune defence. 

If untreated, HIV can lead to AIDS (Acquired Immunodeficiency Syndrome), a condition where the immune system is severely weakened. 

HIV is a lenti-virus (slow and long acting) and belongs to the Retroviruses group. HIV invades the helper T cells to replicate itself thereby limiting the body’s ability to fight infection . HIV is the virus that causes AIDS, and it has no cure

Types of HIV 

1. HIV-1: This is the most common and widespread type of HIV, accounting for the vast majority of HIV infections globally. It is highly infectious and has several subtypes (or clades), labelled A through K. HIV-1 is the primary cause of the global HIV pandemic and is more aggressive in its progression to AIDS compared to HIV-2.
2. HIV-2: This type is less common and primarily found in West Africa. It is less transmissible and generally progresses more slowly to AIDS than HIV-1. There are fewer subtypes of HIV-2, labelled A through H. 

Modes of HIV Transmission

1. Sexual Contact:

• Unprotected Vaginal Sex: HIV can be transmitted through vaginal fluids and semen during unprotected vaginal intercourse..

2. Blood-to-Blood Contact:

• Sharing Needles: Using contaminated needles or syringes, common among intravenous drug users, can transmit HIV.
• Blood Transfusions: Although rare in countries with stringent blood screening, HIV can be transmitted through infected blood transfusions.
• Exposure to Contaminated Blood: Health care workers can be at risk through needle stick injuries or contact with open wounds.

3. Mother-to-Child Transmission:

• During Pregnancy: HIV can cross the placenta from mother to baby.
• During Childbirth: The baby can be exposed to HIV in the mother\’s blood and vaginal fluids during delivery.
• Breastfeeding: HIV can be transmitted through breast milk from an infected mother to her child.

4. Other Modes:

• Contaminated Medical Equipment: Use of non-sterile instruments during medical or dental procedures can transmit HIV.
• Organ and Tissue Transplants: Transplantation of infected organs or tissues, though rare due to screening practices, can transmit HIV.

5. Less Common Modes:

• Tattooing and Piercing: If non-sterile needles are used, there is a risk of HIV transmission.
• Contact Sports: Although extremely rare, transmission can occur if both participants have open wounds.

 

Factors That Facilitate Mother-to-Child Transmission of HIV

Maternal Factors:

1. Viral Load and Immune Status:

• High Viral Load: Higher levels of HIV in the mother’s blood increase the risk of transmission to the baby.
• Low CD4 Count: A weakened immune system due to low CD4 counts enhances transmission risk.
• Maternal Acquisition of HIV: New HIV infections during pregnancy or lactation significantly increase transmission risk.

2. Infections and Inflammation:

• Vaginal Infections: Infections such as bacterial vaginosis can elevate the risk of HIV transmission.
• Chorioamnionitis: Inflammation of the foetal membranes due to infection can facilitate HIV transmission.

3. Access to Antiretroviral Therapy (ART):

• Lack of ART: Mothers who do not receive ART are more likely to transmit HIV.
• Poor Adherence to ART: Inconsistent use of ART reduces its effectiveness in preventing transmission.
• Timing of ART Initiation: Starting ART late in pregnancy or not at all reduces its preventive benefits.

4. Socioeconomic Factors:

• Lack of Healthcare Access: Limited access to prenatal care and HIV testing can lead to missed opportunities for prevention.
• Education and Awareness: Lack of knowledge about HIV transmission and prevention strategies among pregnant women.

5. Nutritional Status:

• Poor Maternal Nutrition: Malnutrition can weaken the mother’s immune system, increasing the risk of transmission.

Labour and Delivery Factors:

6. Delivery Method:

• Vaginal Delivery: Higher risk of transmission compared to elective caesarean section, especially if the mother has a high viral load.
• Prolonged/Difficult Labour: Increased exposure to maternal fluids during extended or complicated labour can raise the risk.

7. Prematurity:

• Premature Birth: Prematurity can increase the risk of transmission due to underdeveloped immune systems in infants.

8. Membrane Rupture:

• Prolonged Rupture of Membranes (PROM): Rupture lasting more than 4 hours before delivery increases the risk of HIV transmission.

9. Invasive Monitoring and Procedures:

• Use of invasive monitoring or procedures during labour can increase the risk of HIV transmission.

Postnatal Feeding Factors:

10. Breastfeeding Practices:

• Prolonged Breastfeeding: Longer duration of breastfeeding increases the risk of HIV transmission.
• Breast Health: Conditions like sore nipples, abscesses, or mastitis can increase the risk.
• Mixed Feeding: Combining breastfeeding with other foods or fluids increases transmission risk. Exclusive breastfeeding for the first 3-6 months does not show excess transmission compared to formula feeding alone.

11. Exclusive Breastfeeding:

•  Exclusive breastfeeding means providing breast milk only, without additional fluids, water, food, teats, or pacifiers, and involves on-demand feeding.

12. Oral Health in Infants:

• Oral Thrush: Presence of oral thrush in breastfed infants can increase the risk of HIV transmission.

Phases of HIV Entry into Host Cells

1. Binding: The HIV virus first attaches to the CD4 receptors on the surface of the host cell, typically a type of immune cell called a CD4+ T lymphocyte. HIV\’s envelope protein, gp120, specifically binds to the CD4 receptor. This interaction triggers a conformational change in gp120 that allows it to also interact with a co-receptor, usually CCR5 or CXCR4, on the host cell surface. This dual receptor binding is essential for the virus to proceed to the next step.
2. Fusion: After binding, the HIV viral envelope fuses with the host cell membrane, allowing the viral contents to enter the host cell. The conformational change in gp120 caused by CD4 and co-receptor binding exposes another viral protein, gp41. gp41 facilitates the merging of the viral envelope with the host cell membrane, creating a fusion pore through which the viral capsid containing the viral RNA and enzymes can enter the host cell cytoplasm.
3. Reverse Transcription: Once inside the host cell, the viral RNA genome is reverse transcribed into DNA. The enzyme reverse transcriptase, carried within the viral capsid, converts the single-stranded viral RNA into double-stranded DNA. This process is error-prone, leading to a high mutation rate which contributes to the virus’s ability to evade the immune system and develop drug resistance.
4. Integration: The newly synthesized viral DNA is integrated into the host cell’s genome. The viral DNA is transported into the host cell nucleus, where the enzyme integrase integrates it into the host cell’s DNA. This integrated viral DNA is known as a provirus and can remain dormant for a period before becoming active.
5. Replication: Once integrated, the viral DNA can be transcribed and translated to produce new viral RNA and proteins. The host cell’s machinery reads the integrated viral DNA and begins to produce viral RNA. Some of this RNA will serve as genomes for new viral particles, while others will be used to produce viral proteins through the process of translation.
6. Assembly: New viral particles are assembled within the host cell. The newly made viral RNA and proteins are transported to the host cell’s surface, where they assemble into new immature viral particles. This assembly process involves the gathering of viral components into a budding virion.
7. Budding: The new viral particles bud off from the host cell, acquiring an envelope from the host cell membrane in the process. The immature viral particles bud off from the host cell, during which they incorporate a portion of the host cell’s membrane as their envelope. The viral enzyme protease then cleaves certain viral precursor proteins into their mature forms, resulting in a fully mature and infectious virus ready to infect other cells.

Clinical Manifestations of HIV/AIDS

The World Health Organization (WHO) has established a staging system to classify HIV infection and disease progression:

Clinical Stage I:

1. Asymptomatic: No symptoms of HIV-related illness.
2. Persistent Generalized Lymphadenopathy: Enlargement of lymph nodes lasting more than three months.
3. Performance Scale 1: Asymptomatic with normal activity level.

Clinical Stage II:

1. Moderate Weight Loss: Less than 10% of presumed or measured body weight lost.
2. Minor Muco-cutaneous Manifestations: Skin conditions like seborrheic dermatitis, prurigo, or fungal nail infections.
3. Herpes Zoster: History of shingles within the last five years.
4. Recurrent Upper Respiratory Tract Infections: Such as bacterial sinusitis, tonsillitis, or otitis media.
5. Performance Scale 2: Symptomatic but normal activity level.

Clinical Stage III:

1. Severe Weight Loss: More than 10% of presumed or measured body weight lost.
2. Unexplained Chronic Diarrhoea: Lasting more than one month.
3. Unexplained Prolonged Fever: Constant or intermittent, lasting more than one month.
4. Oral Candidiasis: Oral thrush, a fungal infection.
5. Oral Hairy Leukoplakia: White patches on the tongue or mouth.
6. Pulmonary Tuberculosis: Active TB infection.
7. Severe Bacterial Infections: Such as pneumonia, pyomyositis, or bacteremia.
8. Acute Necrotizing Ulcerative Gingivitis: Severe gum disease.
9. Unexplained Anaemia, Neutropenia, or Thrombocytopenia: Abnormal blood counts.
10. Performance Scale 3: Bedridden for less than 50% of the day during the last month.

Clinical Stage IV:

1. HIV Wasting Syndrome: Weight loss of more than 10% with chronic diarrhoea or prolonged fever.
2. Pneumocystis Pneumonia (PCP): A severe fungal lung infection.
3. Toxoplasmosis of the Brain: Brain infection caused by the Toxoplasma parasite.
4. Cryptosporidiosis: Parasitic infection causing prolonged diarrhea.
5. Cytomegalovirus Infection: A viral infection affecting various organs.
6. Progressive Multifocal Leukoencephalopathy (PML): Brain infection causing neurological symptoms.
7. Lymphoma: Cancer of the lymphatic system.
8. Kaposi’s Sarcoma: Cancerous skin lesions caused by a herpesvirus.
9. HIV Encephalopathy: Cognitive and/or motor dysfunction due to HIV infection.
10. Atypical Disseminated Leishmaniasis: Parasitic infection affecting multiple organs.
11. Symptomatic HIV-Associated Nephropathy or Cardiomyopathy: Kidney or heart disease associated with HIV.
12. Performance Scale 4: Bedridden for more than 50% of the day during the last month.

Diagnostic Measures for HIV/AIDS

Pre and Post-Counselling and Consent: Essential for all diagnostic procedures unless in specific circumstances:

• Testing of very sick, unconscious, symptomatic, or mentally ill individuals by healthcare teams for better patient management.
• Routine testing for individuals likely to pose a risk of HIV infection to others, such as pregnant and breastfeeding mothers, sexual offenders and survivors, and blood or organ donors. These individuals must still be given the opportunity to know their status.

Criteria for Diagnosis: Diagnosis based on:

• Clinical Staging Criteria.
• Positive HIV Blood Test: Confirmation of HIV infection through serological (antibody) testing.

Testing Protocol: Testing for Adults and Children >18 Months:

• Serological (Antibody) Testing: Most common method. Due to the window period between infection and antibody production, negative individuals should be re-tested after three months if exposed.
• Reactive Rapid Test: Requires confirmation before diagnosis.

Diagnostic Tests

Screening Tests:

• ELISA (Enzyme-Linked Immunosorbent Assay) AglAb Tests: Commonly used to screen blood donations to exclude those in the window period.

Molecular Tests:

• PCR (Polymerase Chain Reaction) Tests: Nucleic-Acid Amplification Testing (NAT) detects genetic material of HIV itself, not antibodies or antigens.

Considerations: Testing should consider:

• Clinical status, medical history, and risk factors of the individual being tested.
• Use of tests in conjunction with patient assessment for accurate diagnosis and appropriate care.

Immediate Connection to HIV Care

• If positive, immediate referral to HIV care services for management and treatment initiation.

HIV Testing Provision Protocol

Step 1: Pre-Test Information and Counseling

• Provide information on HIV transmission, prevention measures, and testing benefits.
• Discuss potential test results, available services, and ensure consent and confidentiality.
• Conduct individual risk assessment and complete necessary documentation.

Step 2: HIV Testing

Perform blood-based testing.

• For infants below 18 months: Use DNA PCR testing.
• For individuals above 18 months: Conduct antibody testing as per testing algorithms.

Step 3: Post-Test Counseling (Individual/Couple)

• Assess readiness to receive results and deliver them simply.
• Address concerns, provide guidance on disclosure, partner testing, and risk reduction.
• Offer information on basic HIV care, ART, and complete documentation.

Step 4: Linkage to Other Services

• Provide information on available services and assist in completing referral forms.
• Upon enrollment in services, record pre-ART enrollment numbers and transfer relevant information to ART registers.

Principles of HIV Testing Services (HTS)

• Confidentiality: Ensure privacy and confidentiality of test results.
• Consent: Obtain informed consent from individuals before testing.
• Counselling: Offer supportive counselling before and after testing.
• Correct Test Result: Ensure accuracy of test results through proper testing procedures.
• Connection to Other Services: Facilitate access to appropriate services for individuals testing positive.

Linkage from HIV Testing to Prevention, Care, and Treatment

Linkage is the process of connecting individuals who test positive for HIV to the necessary services. 

Successful linkage to care ensures that patients receive the services they need. For HIV-positive clients, linkage should occur promptly, within seven days if within the same facility, and within 30 days for referrals between facilities or from the community. Lay providers are recommended as linkage facilitators. 

Types of Linkages:

• Internal Facility Linkage: Connecting patients within the same facility.
• Inter-Facility Linkage: Connecting patients to another facility.
• Community-Facility Linkage: Connecting clients from the community to a health facility.

Internal Facility Linkage Steps:

1. Post-Test Counselling: Provide accurate results and information about available care.
2. Next Steps Discussion: Describe the care and treatment process, emphasizing early treatment benefits.
3. Address Barriers: Identify and overcome any obstacles to linkage.
4. Involvement: Involve the patient and family in decision-making.
5. Documentation: Complete client and referral forms.
6. Escort to Clinic: A linkage facilitator escorts the client to the ART clinic.
7. Enrollment: Register the patient, open an ART file, and provide preparatory counselling.
8. Initiation: Start ART if ready, and continue with counselling support.
9. Integrated Care: Coordinate other services if needed.
10. Follow-Up: Ensure the patient attends appointments.

Inter-Facility and Community-Facility Linkages:

• Inter-Facility Linkage: Refers to connecting patients to another facility. The referring facility should track referred patients and ensure enrollment within 30 days.
• Community-Facility Linkage: Connects clients from the community to a health facility. Utilize community health systems and mobilize peer leaders for outreach and follow-up. Linkage should occur within 30 days after diagnosis.

Treatment Modalities of HIV/AIDS

Treatment Modality	Description
Antiretroviral Therapy (ART)	Suppresses viral load to undetectable levels, reducing morbidity, mortality, and transmission of HIV.
Treatment of Acute Bacterial Infections	Addresses immediate bacterial infections.
Prophylaxis and Treatment of Opportunistic Infections	Prevents and manages opportunistic infections.
Maintenance of Good Nutrition	Ensures adequate nutrition to support overall health.
Immunization	Administers vaccines to prevent opportunistic infections.
Management of AIDS-Defining Illnesses	Addresses specific illnesses associated with advanced HIV infection.
Psychological Support for the Family	Provides emotional support and guidance for affected families.
Palliative Care for the Terminally Ill	Offers comfort and support for patients nearing the end of life.

Antiretroviral Drug Treatment

Goal of ART: Suppress viral load to undetectable levels, reducing morbidity, mortality, and transmission of HIV.

When to Initiate ARV:

• All HIV-infected children below 12 months.
• Clinical AIDS
• Mild to moderate symptoms and immunosuppression.

Process of Starting ART:

1. Assess for opportunistic infections, defer ART if TB or cryptococcal meningitis present.
2. Offer ART on the same day through an opt-out approach.
3. If not ready for same-day initiation, agree on a timely ART preparation plan.

Available ARVs in Uganda

Drug Class	Examples
Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Incorporate into the DNA of the  virus, thereby stopping the building process.	Tenofovir (TDF), Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): stop HIV production by binding directly onto the reverse transcriptase enzyme, and prevent the conversion of RNA to DNA.	Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETV)
Integrase Inhibitors: interfere with the HIV DNA’s ability to insert itself into the host DNA and copy  itself.	Dolutegravir (DTG), Raltegravir (RAL)
Protease Inhibitors (PIs): prevent HIV from being successfully assembled and released from the infected CD4 cell.	Atazanavir (ATV), Lopinavir (LPV), Darunavir (DRV)
Entry Inhibitors:  prevent the HIV virus particle from infecting the CD4 cell.	Enfuvirtide (T-20), Maraviroc

Recommended First Line Regimens in Adults, Adolescents, Pregnant Women and Children

HIV management guidelines are constantly being updated according to evidence and public policy decisions. Always refer to the latest official guidelines.

The 2022 guidelines recommend DOLUTEGRAVIR (DTG) an integrase inhibitor as the anchor ARV in the preferred first and second-line treatment regimens for all HIV infected clients; children, adolescents, men, women (including pregnant women, breastfeeding women, adolescent girls and women of child bearing potential).

Patient Category	Preferred Regimens	Alternative Regimens
Adults and Adolescents
Adults (including pregnant women, breastfeeding mothers, and adolescents ≥30Kg)	TDF + 3TC + DTG	– If DTG is contraindicated: TDF + 3TC + EFV400 – If TDF is contraindicated: TAF + FTC + DTG  – If TDF or TAF is contraindicated: ABC + 3TC + DTG  – If TDF or TAF and DTG are contraindicated: ABC + 3TC + EFV400   – If EFV and DTG are contraindicated: TDF + 3TC + ATV/r or ABC + 3TC + ATV/r
Children
Children ≥20Kg – <30Kg	ABC + 3TC + DTG	– If DTG is contraindicated: ABC + 3TC + LPV/r (tablets)   – If ABC is contraindicated: TAF + FTC + DTG (for children >6 years and >25Kg)   – If ABC and TAF are contraindicated: AZT + 3TC + DTG
Children <20Kg	ABC + 3TC + DTG	– If intolerant or appropriate DTG formulations are not available: ABC + 3TC + LPV/r granules  – If intolerant to LPV/r: ABC + 3TC + EFV (in children >3 years and >10Kg)   – If ABC is contraindicated: AZT + 3TC + DTG or LPV/r

Notes:

• Contraindications for DTG include known diabetics, patients on anticonvulsants (carbamazepine, phenytoin, phenobarbital) – use the DTG screening tool prior to DTG initiation.
• Contraindications for TDF and TAF include renal disease and/or GFR <60ml/min, weight <30Kg.
• TAF can be used in subpopulations with bone density anomalies.
• Children will be assessed individually for their ability to correctly take the different formulations of LPV.

Notes from Ministry of Health

1. For clients on an ABC-3TC-DTG based regimen weighing >25 kg, use the fixed-dose combination of Abacavir/Lamivudine/Dolutegravir 600/300/50 mg instead of the separate pills of Abacavir/Lamivudine 600/300 mg plus Dolutegravir 50 mg.
2. Use Abacavir/Lamivudine 600/300 mg for patients on the following regimens: ABC-3TC-ATV/r, ABC-3TC-LPV/r, and ABC-3TC-DRV/r.
3. Use the single pill of Dolutegravir 50 mg for patients on AZT-3TC-DTG based regimens.
4. For eligible patients on ATV/r and LPV/r, optimize to Dolutegravir.
5. For PrEP, while the guidelines provide options for the use of either TDF/3TC 300/300 mg or TDF/FTC 300/200 mg, use TDF/FTC 300/200 mg for PrEP in terms of programmatic implementation.

Monitoring of ARV Treatment

The monitoring of patients on antiretroviral therapy (ART) serves several purposes:

1. Assess Response to ART and Diagnose Treatment Failure
2. Ensure Safety of Medicines: Identify Side Effects and Toxicity
3. Evaluate Adherence to ART

Methods of Monitoring ARV Treatment

1. Clinical Monitoring: Involves medical history and physical examination.

2. Laboratory Monitoring: Includes various laboratory tests.

1. Viral Load Monitoring: Preferred for assessing response to ART and diagnosing treatment failure.
2. CD4 Monitoring: Recommended in specific scenarios.
3. Other Minor Laboratory Tests: Includes tests for specific indications.

Viral Load Monitoring

• Preferred method for monitoring ART response. A patient who has been on ART for more than 6 months and is responding to ART should have viral suppression (VL <1000 copies/ml) irrespective of the sample type (either DBS or plasma). 
• Provides an early and more accurate indication of treatment failure and the need to switch from first line to second-line drugs, hence reducing the accumulation of drug resistance mutations and improving  clinical outcomes. 
• Early and accurate indication of treatment failure.
• Differentiates between treatment failure and non-adherence.
• Recommended frequency: Every six months for children and adolescents under 19 years.

CD4 Monitoring

• Baseline CD4 count is essential for assessing opportunistic infection risk.
• Recommended for patients with high viral load or advanced clinical disease.

Other Laboratory Tests

Tests	Indication
CrAg	Screen for cryptococcal infection
Complete Blood Count (CBC)	Assess anaemia risk
TB Tests	Suspected tuberculosis
Serum Creatinine	Assess kidney function
ALT, AST	Evaluate liver function
Lipid Profile, Blood Glucose	Assess metabolic health

HIV AND PREGNANCY

In 2004, the WHO reported that 40 million people were infected with HIV/AIDS, including 17.6 million women, 2.7 million children, and 13 million orphans worldwide. In 2005, 700,000 children became infected with HIV, with approximately 95% arising from mother-to-child transmission of HIV (MTCT). Ninety percent of new infections in children occur in Africa due to the near non-existence of PMTCT interventions.

Mother-to-child transmission (MTCT) is the vertical transmission of HIV from mother to child that occurs during pregnancy, childbirth, and breastfeeding. The most probable point of transmission occurs in the late third trimester and even more so during the intrapartum period. In some areas of the world, MTCT has been virtually eliminated thanks to the availability of specific interventions to reduce the risk of transmission. These interventions include:

• Effective voluntary and confidential testing and counselling.
• Access to Antiretroviral Therapy (ART).
• Safe delivery practices.
• Availability and safe use of breast milk substitutes.

Factors Affecting Perinatal Transmission

HIV-related Factors:

• Viral load: The higher the viral load, the greater the risk of transmission.
• Strain variation (genotype): HIV1 or 2.
• Biological growth characteristics.
• CD4 cell count: Lower CD4 count or decreased CD4
  ratio is associated with increased risk of transmission.

Maternal and Obstetric Factors:

• Clinical stage: Primary infection with greater viremia is associated with increased risk.
• STDs: Increased HIV shedding in genital tract epithelial disruption is associated with an increased risk of transmission.
• Sexual behavior: Unprotected sex with multiple partners is associated with increased risk.
• Placental abruption: Disruption of fetal-placental barriers increases exposure to the fetus.
• Duration of membrane rupture: The transmission rate is directly proportional to the increased duration of rupture of membranes, with a 2% increase for each hour increment.
• Gestational age at delivery: Prematurity is associated with increased risk.
• Invasive procedures in labor such as episiotomy, vacuum delivery, artificial rupture of membranes.
• Modes of delivery: A study in developed countries shows that elective cesarean section done prior to rupture of membranes and labor significantly reduces the risk of perinatal transmission. Planned cesarean section surgery must be considered in the context of the woman’s life and availability of local resources.
• Knowledge of HIV status combined with accessibility to and acceptance of ART decreases transmission.
• Substance abuse: Substance use during pregnancy is associated with increased risk.

Maternal and Neonatal Factors:

• Immature immune system (especially in preterm babies).
• Genetic susceptibility.

Breastfeeding:

• Without ART, the risk of transmission through breastfeeding by an infected mother may increase the risk to a total of 20-45%.
• Where breastfeeding is common and prolonged, transmission through breastfeeding may account for up to half of HIV infections in infants and young children.
• Early findings show a low rate of transmission through breastfeeding in the first 3 months in infants receiving prophylaxis with either Lamivudine or Nevirapine.
• The risk can be reduced to under 2% by a combination of antiretroviral prophylaxis during pregnancy and delivery, and to the neonate, with elective cesarean section and avoidance of breastfeeding.
• Availability of safe breast milk substitutes must be considered, including a safe water supply, when educating and counseling women to avoid breastfeeding.

Strategies for Prevention of Mother-to-Child Transmission (PMTCT):

1. Primary prevention of HIV among prospective parents.
2. Prevention of unwanted pregnancy among HIV-infected women.
3. Prevention of MTCT among HIV-infected mothers through:

• Provision of voluntary confidential counseling and testing.
• Antiretroviral agents.
• Safe delivery practices.
• Safe infant feeding practices.
• Support for the affected family and the community at large. Education and counseling services may help the woman’s family understand the issues and thus support the woman in her choice to prevent transmission of HIV to her baby.

Components of a Comprehensive HIV Prevention Program:

1. Health education, provision of information, and counseling on HIV prevention and care, including MTCT.
2. Voluntary confidential counseling and testing services that are acceptable and accessible.
3. Quality and focused antenatal care.
4. Safe delivery practices.
5. Support and counseling on infant feeding practices.
6. Family planning services.
7. Community mobilization and education to decrease stigma and discrimination against, as well as to increase support for, HIV-positive clients.

PULMONARY TUBERCULOSIS

Pulmonary Tuberculosis is an infectious disease of the lungs caused by acid-fast bacilli known as Mycobacterium.

INCIDENCE: 

The incidence ranges between 1% and 2% amongst the hospital deliveries in the tropics, being confined predominantly to the underprivileged sectors of society. Incidence of tuberculosis is rising worldwide with the rising prevalence of HIV infected patients. In 2000, WHO showed the emergence of multidrug resistant tuberculosis (MDR-TB) all over the world. It is a “global health emergency”.

Causes of Tuberculosis in Pregnancy:

TB is caused by the bacterium Mycobacterium tuberculosis. This bacteria spreads through the air when an infected person coughs, sneezes, talks, or sings, releasing tiny droplets containing the bacteria. When a healthy person inhales these droplets, the bacteria can enter the lungs and cause infection.

Incubation Period:

• The time between exposure to M. tuberculosis and the onset of symptoms is usually 4-6 weeks, but it can vary widely depending on individual factors.

Mode of Spread:

• Droplet Infection: The primary mode of transmission is through airborne droplets released when an infected person coughs, sneezes, talks, or sings. These droplets contain the bacteria, which can be inhaled by a healthy person.
• Sputum in Open Air Spaces: The presence of infected sputum in shared spaces can also facilitate transmission.
• Drinking Unpasteurized Milk: While less common, bovine tuberculosis can be transmitted through unpasteurized milk.
• Inhalation: Inhalation of contaminated dust containing M. tuberculosis can also lead to infection.

Types of Tubercle Bacterium:

1. Human Tuberculosis: This is the most prevalent form of TB, primarily spread through person-to-person contact through droplet infection.
2. Bovine Tuberculosis: This form is spread through infected animals, primarily cattle, and can be transmitted to humans through consumption of unpasteurized milk or contact with infected animals.

Types of Tuberculosis:

Pulmonary TB: This is the most common form of TB, affecting the lungs.

Signs & Symptoms:

• Persistent Cough: A cough that lasts for more than 3 weeks, often with the production of sputum.
• Sputum: Sputum may be purulent (containing pus), blood-stained (hemoptysis), or both.
• Evening Fevers: Fluctuations in body temperature, with fever typically occurring in the evening.
• Low-grade Fever and Malaise: Feeling unwell with a persistent low-grade fever and fatigue.
• Night Sweats: Excessive sweating during the night.
• Weight Loss: Significant and unexplained weight loss.
• General Lymphadenopathy: Swelling of lymph nodes throughout the body.
• Loss of Appetite: Decreased appetite and difficulty eating.
• Pleural Effusion: Fluid accumulation in the space between the lungs and the chest wall.
• Anemia and Massive Hemoptysis: Severe blood loss from the lungs, along with a decrease in red blood cells.
• Enlargement of Cervical Glands: Swelling of lymph nodes in the neck.
• Family History of Tuberculosis: Having a close family member with a history of TB increases the risk of infection.
• Amenorrhea: Absence of menstruation, particularly in women who are of reproductive age.

Extra Pulmonary TB: This form of TB affects organs other than the lungs. While less common than pulmonary TB, it can be serious and life-threatening.

Affected Areas:

• Meninges (Meningitis): Inflammation of the membranes surrounding the brain and spinal cord.
• Abdominal Pelvic Organs: Can affect the intestines, stomach, liver, and reproductive organs.
• Peritoneum: Inflammation of the membrane lining the abdominal cavity.
• Spine (Tuberculous Spondylitis): Infection of the vertebrae, often resulting in pain, stiffness, and deformity.
• Lymph Nodes: Swelling and inflammation of lymph nodes, particularly in the neck, armpits, and groin.
• Bones: Can affect bones throughout the body, leading to pain, swelling, and joint dysfunction.

Risk Factors for Tuberculosis in Pregnancy:

• Pre-existing TB infection: A previous history of TB infection, even if treated, increases the risk of reactivation during pregnancy.
• Exposure to infected individuals: Living with or working closely with someone who has TB increases the risk of infection.
• Weakened Immune System: Pregnancy can temporarily suppress the immune system, making it easier for the TB bacteria to take hold and multiply.
• Malnutrition and Anaemia: Pregnant women who are malnourished or anaemic have a weaker immune system, making them more susceptible to TB infection.
• HIV Infection: HIV infection weakens the immune system significantly, increasing the risk of TB infection and making the disease more difficult to treat.
• Other Underlying Health Conditions: Conditions like diabetes, chronic kidney failure, and alcoholism can weaken the immune system and increase the risk of TB infection.
• Socioeconomic Factors: Poverty, overcrowding, poor sanitation, and inadequate access to healthcare can all contribute to the spread and development of TB.
• Environmental Factors: Exposure to dust, smoke, and other airborne irritants can irritate the lungs, making them more susceptible to TB infection.

Diagnosis of Tuberculosis in Pregnancy:

• Tuberculin Skin Test (TST): The TST involves injecting a small amount of purified protein derivative (PPD) under the skin. A positive reaction (induration ≥ 5 mm) indicates exposure to TB, especially in high-risk individuals (e.g., those with HIV).
• Chest X-ray: A chest X-ray can reveal abnormalities in the lungs consistent with TB infection. However, it is usually performed after 12 weeks of pregnancy to minimize potential risks to the fetus.
• Sputum Culture: Early morning sputum samples are collected for three consecutive days and examined for the presence of acid-fast bacilli (AFB), the hallmark of TB.
• Gastric Washings: For individuals who cannot produce sputum, gastric washings can be analyzed for AFB.
• Diagnostic Bronchoscopy: In some cases, a bronchoscopy, a procedure that allows for visualization of the airways, may be necessary to obtain tissue samples for diagnosis.
• Extrapulmonary TB Diagnosis: TB can affect other organs like lymph nodes and bones (although rare in pregnancy).
• Direct Amplification Tests: These tests, like PCR (polymerase chain reaction), amplify DNA specific to M. tuberculosis, allowing for sensitive and specific detection.

Investigations:

• Sputum examination will reveal the bacilli.
• Examination of aspirates for pleural effusion.
• Tuberculosis skin test (to show whether the patient has been in contact with tuberculosis bacilli).
• Biopsy, e.g., of lymph nodes.
• Serology for HIV.
• Blood smear for malaria parasites.
• Chest X-ray examination.
• Erythrocyte sedimentation rate (ESR).
• Haemoglobin (HB).
• Urinalysis.
• Stool examination.

Management in Maternal/Child (M/C) Care:

Aims:

• Health education about the disease.
• Promote healing.

Procedure when a Mother Comes:

• Create a nurse-patient relationship and take history (family, social, medical, and obstetrical).
• Observations: Take TPR (temperature, pulse, respiration) and BP (blood pressure).
• Conduct general and abdominal examinations.
• Reassure the mother, document all findings, and refer her to a hospital.

In Hospital: During Pregnancy:

• If sputum is negative, she can be treated as an outpatient before delivery, under the care of a physician and obstetrician.
• She should visit ANC (Antenatal Care) regularly.
• If she is infectious, she should be admitted to an isolation room.
• Histories and observations (BP, TPR) are taken.
• General and abdominal examinations are done, and the doctor is informed.
• Prepare an examination tray for taking specimens for observations.
• When the doctor comes, he examines the patient.

Medical Treatment: New Cases:

• 2EHRZ 6EH 

1. Ethambutol (E) 25mg/kg. 
2. Isoniazid (H) 300mg.
3. Rifampicin (R): <50kg: 450mg; ≥50kg: 600mg.
4. Pyrazinamide (Z): <50kg: 1.5g; ≥50kg: 2.0g.

Other Treatment for TB: 

• Relapse: Patients treated before, who had initial care but the disease reoccurred later. 
• Defaulters: Patients who stop treatment regardless of the reason.
• Treatment: 2SE (HR) Z/IE (HR) Z/5EHR. Streptomycin 60 injections dose 0.75g (not given in pregnancy due to side effects).

Failures: Patients with positive sputum 2 months after starting treatment.

• Treatment: 2 months SE (HR) Z/E (HR) 5 months SE (HR).

Side Effects of Drugs:

• Some other drugs: pyridoxine, prednisone for TB meningitis, codeine phosphate to reduce the rate of spread of infectious bacteria.
• All patients must be counseled before starting treatment to ensure understanding of the number of drugs, duration of treatment, and expected side effects.

Nursing Care:

• Isolation room should be ventilated.
• Diet: Plenty of protein and fluids; intake and output should be well recorded.
• Rest and sleep: Important during day and night, with occupational therapy.
• Hygiene: Daily bath, oral hygiene, spitting in a sputum mug (emptied and disinfected regularly), using disposable handkerchiefs that should be burned, changing and disinfecting bed sheets.
• Exercise: Teach deep breathing to expand the lungs.
• Position: Sitting up if dyspneic.
• Observations: Take T, R, P, and BP; assess general condition and fetal well-being twice a week.
• Bowel and bladder: Encourage regular bowel and bladder function.
• Reassurance: Provide support and encouragement to the mother.

During Labour: Problems May Include:

• Fatigue
• Reduced lung function

Doctor\’s Case:

• Inform the doctor, physician, obstetrician, and paediatrician once labour starts.
• Manage the first stage as usual, with Oxygyen if ordered by the doctor. Use sitting up position if dyspneic.
• In the second stage, use episiotomy, forceps, or vacuum extraction to reduce over-straining from pushing.
• Perform C-section only for specific obstetrical indications, e.g., fetal distress.
• Actively manage the third stage to prevent unnecessary blood loss.

During Puerperium:

• Manage as other mothers.
• If the mother has an active infection, she should breastfeed with a mask, and the baby should be taken back to the nursery.
• No Contraindication: Breastfeeding is not contraindicated when a woman is taking anti-tuberculous drugs.
• Avoidance: Breastfeeding should be avoided if the infant is also receiving anti-tuberculosis medications to prevent drug accumulation.
• Active Lesions: Breastfeeding is contraindicated in cases of active TB. The infant should be isolated from the mother after delivery and given prophylactic isoniazid (10-20 mg/kg/day) for 3 months.
• Chemotherapy: If the mother has been on effective chemotherapy for at least two weeks, there is no need to isolate the baby.
• If the mother’s sputum is positive, give the baby BCG at birth and protect with isoniazid syrup (2.5mg/kg/day). The vaccine becomes effective in 3-6 weeks; if any family member is infected, separation is advised.
• Mantoux test is carried out after 6 weeks.
• If the mother is negative or inactive, she can stay with her baby.
• Advise rest and sleep, and a well-balanced diet to avoid recurrence of active disease.
• Avoid pregnancies until the disease has been controlled for 2 years.
• Long-term medical and social follow-up is necessary to monitor the disease and its treatment.

Effects of TB on Pregnancy:

Maternal Effects on Pregnancy:

• General Debilitation: TB weakens the mother\’s overall health, making it challenging to cope with the demands of pregnancy.
• Placental Insufficiency: TB can impair placental function, leading to:

1. Premature Labor: Increased risk of delivering before term.
2. Intrauterine Fetal Death: Loss of the fetus during pregnancy.
3. Intrauterine Growth Retardation (IUGR): The fetus fails to grow at an appropriate rate due to inadequate nutrient and oxygen supply.

• Fetal Hypoxia: Reduced oxygen levels in the fetus due to placental insufficiency.
• Asphyxia: Severe oxygen deprivation in the fetus, potentially leading to brain damage or death.

During Labour:

• Increased Risk of Assisted Deliveries: TB-related complications can increase the need for interventions like forceps or vacuum extraction.
• Maternal and Fetal Distress: Both the mother and the fetus may experience complications during labor, such as heart rate abnormalities, due to TB-related physiological changes.
• High Prenatal Mortality Rate: The risk of stillbirth is significantly elevated in mothers with TB.

Note: Pregnant or breastfeeding women with TB should be treated with short-course chemotherapy (e.g., Rifampicin, Isoniazid, Pyrazinamide, Ethambutol).

Effects on Puerperium:

• Anaemia: TB can worsen existing anaemia or lead to new iron deficiency in the postpartum period.
• Poor Lactation: TB can impair breast milk production, impacting infant nutrition.
• Lowered Resistance to Infection: The mother\’s immune system is compromised, increasing her susceptibility to infections during the postpartum period.

Prevention:

In the Community:

1. Sensitize and mobilize the community to create awareness about TB.
2. Health education on ensuring well-ventilated homes, avoiding overcrowding, proper disposal of sputum, covering the mouth when coughing/sneezing, and screening family members.
3. Encourage good nutrition, drinking pasteurized milk products, disinfecting patients’ belongings, and immunizing children with BCG.
4. Ensure adequate management of chest infections and encourage mothers to attend ANC.

In Hospital:

1. Encourage mothers to attend ANC for thorough examinations, histories, and investigations for management.
2. Keep the hospital environment clean and dispose of refuse properly.
3. Ensure ward cleanliness by scrubbing floors, dusting windows, and cleaning equipment daily.
4. Health workers should avoid droplet infections, wash hands after every procedure, and isolate TB patients.

Complications:

• Spontaneous Pneumothorax: A collapsed lung due to air leaking into the space between the lung and chest wall.

• Pleural Effusion: Fluid buildup in the space between the lung and chest wall.
• Gastrointestinal TB: TB infection affecting the digestive system.
• Massive Hemolysis: Breakdown of red blood cells, leading to anemia and potentially fatal complications.
• TB Meningitis: Infection of the membranes surrounding the brain and spinal cord.
• TB Pericarditis: Inflammation of the sac surrounding the heart.
• Anaemia: Iron deficiency, which can be exacerbated by TB infection.
• Death: In severe cases, TB can be fatal, especially in pregnant women who are immunocompromised.
• Hemoptysis: Coughing up blood due to lung damage.
• High Maternal Mortality Rate: The risk of death from TB is significantly elevated in pregnant women.

MALARIA IN PREGNANCY

Malaria is a febrile condition/disease caused by a Plasmodium parasite and is the most common cause of pyrexia in tropical regions, usually associated with rigors.

CAUSES 

Malaria is caused by Plasmodium parasites (protozoa), which are of four types: 

1. Plasmodium falciparum: This is the most dangerous species, responsible for the majority of malaria deaths worldwide. It can cause severe complications, including cerebral malaria, which can lead to coma and death. During pregnancy, P. falciparum infections are particularly dangerous, increasing the risk of low birth weight, preterm birth, and stillbirth.
2. Plasmodium vivax: This species is less deadly than P. falciparum but can still cause serious illness. It is characterized by relapses, where symptoms can reappear months after the initial infection. During pregnancy, P. vivax can cause anemia and increase the risk of miscarriage.
3. Plasmodium ovale: This species is similar to P. vivax in its symptoms and ability to cause relapses. It is less common than P. vivax and P. falciparum.
4. Plasmodium malariae: This species is the least common and usually causes a milder form of malaria. However, it can cause severe complications in some cases, particularly in pregnant women.

MODE OF ENTRY 

Malaria parasites are transmitted by a female Anopheles mosquito. The mosquito spits saliva onto human skin to soften it. Since malaria parasites are stored in the saliva, they are introduced through the proboscis while the mosquito sucks blood, which is used by the female mosquito for egg maturation.

MALARIA CYCLE 

There are two cycles: 

1. Malaria cycle in the mosquito (Sexual stage – union of male and female gametes to form a zygote)
2. Malaria cycle in humans (Asexual stage)

MALARIA CYCLE IN THE MOSQUITO (SEXUAL STAGE) 

When a mosquito bites an infected person, it acquires gametocytes (sexual cells of a malaria parasite). After ingestion, these gametocytes travel through the blood to the mosquito\’s stomach, where they unite and form a zygote on the stomach walls.

Zygote → Ookinete → Oocyst → Sporozoite (mature malaria parasite still within the mosquito). 

The sporozoites move to the mosquito\’s salivary glands, ready to be injected into a healthy person.

MALARIA CYCLE IN HUMANS (ASEXUAL STAGE) 

An infected mosquito bites a healthy person, introducing sporozoites that spread within the body in approximately 30 minutes. These sporozoites enter the bloodstream and are transported to the liver for further development, known as PRIMARY TISSUE SCHIZONTS. The parasites develop and mature within liver cells, eventually destroying them. After about 7-14 days (incubation period), the parasites rupture from the liver cells as merozoites, entering the bloodstream to infect red blood cells.

Chronic malaria: Merozoites are the mature malaria parasites. They attack and feed on red blood cells until they destroy them completely, releasing waste products and causing the body to react.

CAUSES OF FEVER IN MALARIA

• Presence of malaria parasites in the body is recognized as foreign by the immune system.
• The rupture of red blood cells as the parasite destroys them triggers a response.
• The release of toxins from the parasites causes fever due to waste products and destroyed haemoglobin.

SIGNS & SYMPTOMS OF MALARIA

 They range from mild to severe.

MILD TO MODERATE SIGNS & SYMPTOMS

• Fever: Low-grade fever, often intermittent or fluctuating
• Headache: Often severe and persistent
• Joint pain: Muscles and joints may ache
• Nausea and vomiting: Feeling sick to the stomach with or without throwing up
• Anorexia: Loss of appetite
• Abdominal issues: Constipation or diarrhea
• Malaise: Feeling generally unwell and weak
• Dizziness: Feeling lightheaded or unsteady
• Nightmares: Disturbing dreams while sleeping

SEVERE MALARIA SYMPTOMS:

• High fever: Persistent high temperature
• Severe headache: Intense and unrelenting headache
• Confusion and disorientation: Difficulty thinking clearly
• Seizures: Uncontrolled muscle spasms
• Coma: Loss of consciousness
• Jaundice: Yellowing of the skin and eyes
• Rapid breathing: Increased breathing rate
• Kidney failure: Inability of the kidneys to filter waste
• Blood in urine: Blood appearing in the urine
• Severe anemia: Low red blood cell count

SEVERE SIGNS AND SYMPTOMS 

Can also be characterized in four stages:

1. COLD STAGE: Patient feels very cold, increased pulse, nausea, and goosebumps.
2. RIGOR STAGE: Shivering attacks, fast pulse, nausea, and possible vomiting.
3. HOT STAGE: Temperature rises between 38-40°C, severe headache, vomiting, restlessness, and convulsions in children.
4. SWEATING STAGE: Temperature lowers, sometimes to normal or subnormal levels, lasting 3-4 hours, with or without treatment.

TREATMENT OF MALARIA 

Classified into: 

A. Uncomplicated malaria

B. Severe and complicated malaria

C. Intermittent preventive treatment

D. Severe malaria in pregnant women and children under 4 months

Uncomplicated Malaria

• Artemether/Lumefantrine (50mg per tablet): Start with 200mg, then 100 mg daily.
• Artesunate + Amodiaquine (similar to Artemether).

Second Line

• Quinine (300mg per tablet): 600 mg dose every 8 hours for 7 days.

Severe and Complicated Malaria

• Artemisinin combination therapies (ACTs)
• Parenteral Artemether (IM or IV)
• Quinine (600mg, adjusted by body weight)

Intermittent Preventive Treatment

• Fansidar (1500mg, 3 tablets taken at once from 4 months or 16 weeks).

Severe Malaria in Pregnancy

• Parenteral Quinine (600 mg every 8 hours): Given in the 1st trimester. After the 1st trimester, ACTs can be administered.
• For children under 4 months or weighing below 5kg, Quinine is given.

SIGNS OF UNCOMPLICATED MALARIA

• Fever: Intermittent or fluctuating fever, may be low-grade or high.
• Headache: Often severe and persistent.
• Chills: Episodes of shivering and cold sensations.
• Sweats: Episodes of profuse sweating.
• Muscle aches: Muscle soreness and pain.
• Fatigue: Feeling tired and weak.
• Nausea and vomiting: Feeling sick to the stomach with or without throwing up.
• Diarrhea: Loose stools.
• Loss of appetite: Decreased hunger.
• Dehydration: Loss of body fluids, leading to dry mouth and skin.
• Abdominal pain: Pain in the stomach area.

SIGNS OF COMPLICATED MALARIA

• Severe anemia: Low red blood cell count, leading to fatigue, weakness, and pale skin.
• Jaundice: Yellowing of the skin and eyes due to bilirubin buildup.
• Renal failure: Kidney failure, leading to decreased urine output and waste buildup.
• Cerebral malaria: Parasites infect brain cells, causing confusion, seizures, coma, and death.
• Pulmonary edema: Fluid buildup in the lungs, leading to difficulty breathing.
• Shock: Life-threatening condition where the body is unable to circulate blood effectively.
• Metabolic acidosis: Build-up of acid in the blood, leading to various complications.
• Hypoglycemia: Low blood sugar, potentially leading to seizures and coma.
• Respiratory distress: Difficulty breathing, including rapid breathing and wheezing.
• Bleeding: Increased risk of bleeding, including gastrointestinal bleeding.
• Behavioural changes: Confusion, disorientation, delirium, and hallucinations.
• Prostration: (trying to touch something that isn\’t there)

MANAGEMENT

The midwife manages mild cases of malaria and treats it as an outpatient. She treats malaria between 16-36 weeks of pregnancy due to the new drug policy.

First Line Drug

• Refer mothers below 16 weeks and above 36 weeks of pregnancy for hospital management.

Steps for Management: 

1. Welcome the mother, offer a seat, greet, and introduce yourself. 
2. Take history (personal, problem, environment, pregnancy). 
3. Make observations (TPR, BP, weight) and interpret them. 
4. Conduct general and abdominal examinations to decide on treatment or referral. 
5. Treat symptoms like fever, headache, and anaemia. 
6. Administer appropriate medications (e.g., iron supplements, antimalarials).

NEW MALARIA TREATMENT POLICY

• Uncomplicated Malaria

1. First-line treatment: Artemether or Artesunate + Amodiaquine
2. Second line: Quinine

• Severe Malaria

1. Parenteral Quinine
2. Parenteral Artemisinin derivatives (ACTs)

• Uncomplicated/Severe Malaria in Special Groups

1. Pregnant women in the first trimester are given Quinine. ACTs can be used after the 1st trimester.
2. For children under four months, Quinine is given while ACTs are contraindicated.

FOR SEVERE COMPLICATED MALARIA,

• Admit the patient
• Take history (personal, pregnancy, complications)
• Inform the doctor
• Prepare for examination and treatment
• Administer emergency treatment and anti-malarial medications
• Manage complications and provide supportive care

Emergency Treatment

• Resuscitation with attention to the airway
• IV infusion introduction
• Effective anti-malarial medication administration based on body weight
• Correct hypoglycemia with Dextrose
• Correct/prevent dehydration
• Reduce high body temperature with antipyretics
• Control convulsions with Diazepam
• Determine the need for blood transfusion

Supportive Care

• Comfortable bed with a treated mosquito net
• Clean environment and proper hygiene
• Complete bed rest, daily baths, and tepid sponging
• Oral hygiene every 4 hours
• Adequate diet with small servings, sweetened foods, fruits, and vitamin supplements
• Monitor bowel and bladder functions
• Provide passive and active exercises
• Regular observations (TPR, BP, fetal heart, weight, jaundice, blood smears)
• Discharge with advice on diet, rest, medication, and mosquito net usage

COMPLICATIONS OF MALARIA

Effects on Pregnancy: 

To the mother:

• Increased Risk of Severe Malaria: Pregnancy significantly increases the susceptibility to severe malaria, putting mothers at higher risk of complications like cerebral malaria, pulmonary edema, and renal failure.
• High Temperatures: Fever associated with malaria can cause intense discomfort and dehydration, particularly for pregnant women who are already experiencing hormonal changes and increased body temperature.
• Anaemia: Malaria parasites destroy red blood cells, leading to anaemia, which can be exacerbated during pregnancy when blood volume increases. Severe anaemia can lead to fatigue, weakness, and shortness of breath, further jeopardizing the mother\’s health.
• Puerperal and Cerebral Malaria: These life-threatening conditions pose a high risk to pregnant women. Puerperal malaria occurs during or after childbirth, while cerebral malaria involves the brain and can lead to coma and death.
• Antepartum and Postpartum Haemorrhage: Malaria increases the risk of bleeding before or after childbirth, leading to severe blood loss and potential complications for both mother and baby.
• Ill Health and Compromised Immunity: Malaria symptoms, including nausea, vomiting, diarrhoea, and loss of appetite, can affect a pregnant woman\’s health and worsen nutritional deficiencies. The weakened immune system makes her more susceptible to infections.
• Jaundice and Dehydration: The buildup of bilirubin, a breakdown product of red blood cells, can cause jaundice, which further compromises the mother\’s health and can impact the baby\’s development. Dehydration, a common symptom of malaria, can lead to complications for both the mother and fetus.

To the baby:

• Abortions: Malaria increases the risk of miscarriage, especially during the first trimester.
• Prematurity: Malaria can trigger premature labor, leading to babies born before 37 weeks of pregnancy, increasing their risk of health problems.
• Intrauterine Fetal Death (IUFD): Malaria can lead to the death of the baby in the womb, especially in the third trimester.
• Low Birth Weight: Babies born to mothers with malaria are more likely to have low birth weight, increasing their risk of health problems and long-term developmental issues.
• Congenital Malaria: The baby can be infected with malaria parasites in the womb, leading to complications at birth or later in life.
• Intrauterine Growth Restriction (IUGR): Malaria can hinder the baby\’s growth in the womb, leading to smaller size at birth, impacting their long-term health and development.

Effects on the Ward:

• Extended Hospital Stays: Malaria complications can lead to prolonged hospital stays, burdening healthcare resources and increasing the risk of infections.
• Blockage of Space for Urgent Obstetric Cases: Long stays by malaria patients can limit space and resources for urgent obstetric cases, delaying critical care for other mothers.
• Ward Congestion and Cross-Infection: Overcrowding due to malaria cases can increase the risk of cross-infection, affecting the health of other patients and healthcare workers.
• Financial Strain on Families: Treatment and hospitalization for malaria can strain the finances of families, especially in developing countries where access to healthcare is limited.
• Deprivation of Maternal Care for Children at Home: Mothers hospitalized for malaria are unable to care for their other children, potentially leading to neglect and health issues.
• Economic Inefficiency: Malaria during pregnancy not only affects individual families but also impacts economic productivity due to lost work days, reduced income, and increased healthcare costs.

EPILEPSY IN PREGNANCY

Epilepsy is a chronic disorder characterized by recurrent, unpredictable seizures due to temporary dysfunction of the brain\’s neurons producing excessive electrical discharge. 

Although it typically presents in childhood, it has a second peak in older adults, with women of childbearing age accounting for 23% of those affected. The prevalence of epilepsy in pregnancy is 0.35%.

Types of Epilepsy

A. Partial Epilepsy

1. Simple Partial Seizures:

• Consciousness remains intact.
• Experiences an aura (premonition).
• Sensations like pins and needles in the arms or legs.
• Pallor or a flushed face with sweating.
• Muscle twisting in limbs with some stiffness.

2. Complex Partial Seizures:

• Loss of memory of the event.
• Hand rubbing.
• Chewing and smacking of lips.
• Random noises.
• Unusual posture.

B. Generalized Epilepsy

1. Absence Seizures:

• Staring and blinking.
• Daydreaming with loss of awareness for 5-20 seconds (mainly affects children).

2. Myoclonic Seizures:

• Brief muscle jerking in an arm or leg, lasting a fraction of a second while remaining conscious.
• All body muscles contract for less than 20 seconds without convulsions, causing the individual to fall.

3. Tonic-Clonic Seizures:

• Whole body contracts, arms and legs convulse.
• Incontinence is possible.
• Lasts 1-2 minutes, leaving the individual tired and wanting to sleep.
• The most common type of seizure (60% of cases).

4. Atonic Seizures:

• Sudden loss of muscle tone, causing the individual to fall limply.
• Head injury is probable, but the individual gets up immediately with no confusion.

Causes of Epilepsy in Pregnancy

1. Idiopathic: Most cases have no underlying cause.
2. Genetic Predisposition: 30% of cases have a family history of epilepsy.
3. Secondary Epilepsy: Can be encountered in pregnancy in patients with:

• Previous brain surgery.
• Intracranial mass lesions (e.g., meningiomas and arteriovenous malformations).
• Antiphospholipid syndrome.

Other Causes of Seizures in Pregnancy

• Eclampsia.
• Cerebral vein thrombosis (CVT).
• Thrombotic thrombocytopenic purpura (TTP).
• Stroke.
• Subarachnoid hemorrhage.
• Drug and alcohol withdrawal.
• Hypoglycemia.
• Infections (e.g., tuberculoma, toxoplasmosis).
• Gestational epilepsy (seizures confined to pregnancy).

Diagnosis

Most women are already diagnosed with epilepsy. However, if a first seizure occurs during pregnancy, the following investigations are appropriate:

• Blood pressure, urinalysis, platelet count, clotting screen, blood film.
• Blood glucose, serum calcium, serum sodium, liver function tests.
• CT or MRI of the brain.
• EEG (electroencephalogram).

Effects of Epilepsy on Pregnancy

On the Fetus:

• No increased risk of miscarriage or obstetric complications unless a seizure results in abdominal trauma. This is a positive aspect, indicating that epilepsy itself doesn\’t inherently increase the risk of these complications.
• Fetal malformations: These can include a range of abnormalities affecting various organs and systems.
• Intrauterine growth restriction (IUGR): This refers to the fetus not growing at the expected rate, potentially leading to low birth weight.
• Oligohydramnios: This is a condition where there is too little amniotic fluid surrounding the fetus, which can be associated with developmental issues.
• Preeclampsia: This is a serious condition characterized by high blood pressure and protein in the urine, which can affect both mother and fetus.
• Stillbirths: This refers to the death of a fetus before birth.

On the Newborn:

• Birth defects are increased two-fold. This could be related to the severity of the disease and also due to the anticonvulsants used. Pattern of abnormalities is related to the type of anticonvulsant drugs (valproate 5.9%, Carbamazepine, 2.3% and Lamotrigine 2.1%).
• The malformations include—Cleft lip and/or palate, mental retardation, cardiac abnormalities, limb defects and hypoplasia of the terminal phalanges. Sodium valproate is associated with neural tube defects. 
• There is chance of neonatal hemorrhage and is related to anticonvulsant induced reduction of coagulation factors (vitamin K dependent). The risk of developing epilepsy to the offspring of an epileptic mother is 10%.

On the Mother:

• Increased risk of seizures during pregnancy and postpartum. Hormonal changes and physiological stress associated with pregnancy can trigger seizures.
• Potential for worsening of epilepsy. Some women may experience an increase in seizure frequency or severity during pregnancy.
• Difficulty in managing epilepsy medication during pregnancy. Many anticonvulsants are teratogenic (can cause birth defects), requiring careful consideration and monitoring.
• Increased risk of postpartum depression. This can be exacerbated by the challenges of managing epilepsy and raising a child.

• Stress and anxiety associated with pregnancy and childbirth. The fear of seizures and their potential impact on the baby can contribute to maternal stress.

Management of Epilepsy in Pregnancy

Pre-Pregnancy Counseling

1. Control of Epilepsy:

• Maximize seizure control with the lowest dose of the most effective treatment.
• Review antiepileptic drugs (AEDs) considering the risk of teratogenesis and adverse neurodevelopmental effects.

2. Stopping Treatment:

• AEDs should be withdrawn slowly to reduce the risk of withdrawal-associated seizures, particularly important for benzodiazepines and phenobarbitone.
• Current recommendations suggest stopping driving from the start of the drug withdrawal period and for six months after cessation of treatment if there are no seizures.

Newer Drugs with Safety Profiles:

• Topiramate: 100–400 mg/day.
• Levetiracetam: 1–3 gm/day, not an enzyme inducer.

Folic Acid: All women on AEDs should take pre-conception folic acid 4 mg daily starting before pregnancy and continuing throughout pregnancy.

Antenatal Management

1. Medication:

• Keep the dose of chosen drugs as low as possible and monitor serum levels regularly.
• Commonly used drugs include:

1. Phenobarbitone (60-100mg daily in divided doses).
2. Phenytoin (150-300mg daily in divided doses).
3. Carbamazepine (0.8-1.2g daily in divided doses).

• Continue folic acid daily before conception and throughout pregnancy to prevent folate-deficiency anemia.

2. Seizure Control:

• IV Phenytoin: Administer a slow loading dose of 15–20 mg/kg for effective, long-duration control with fewer side effects.
• Benzodiazepines: 10–20 mg slow IV if phenytoin is not effective.

3. Support:

• Educate relatives, friends, and partners on placing the woman in the recovery position to prevent aspiration during a seizure.
• Administer Vitamin K (10 mg daily) orally in the last two weeks of pregnancy.
• Intrapartum Management

4. Seizure Risk:

• The risk of seizures increases around delivery. Women with major convulsive seizures should deliver in a hospital.
• Continue anticonvulsant medication throughout labor with regular review by the obstetric team.
• Administer short-acting benzodiazepines if seizures recur.

5. Labor and Delivery:

• Women should not be left alone during labor, and dehydration, hyperventilation, and exhaustion should be avoided as they can trigger seizures.

6. Vitamin K: 

• 10 mg daily orally to the mother in the last two weeks of pregnancy.
• Infant: 1 mg IM at birth to prevent neonatal hemorrhage
• Birth can be spontaneous, facilitated by the midwife. Administer vitamin K to the baby promptly after birth to protect against AED-induced hemorrhagic disease.
• Caesarean section is only necessary for recurrent generalized seizures in late pregnancy or labor.

Postpartum Management

7. Seizure Risk:

• The risk of seizures increases in the first 24 hours after birth, so the woman should remain in the hospital.
• Encourage breastfeeding.
• Monitor the baby closely and report any concerns to the pediatrician immediately.
• Provide safety advice for caring for the baby in case of maternal seizures.

8. Breastfeeding:

• There is no contraindication for breastfeeding.
• Infant: May be drowsy due to medication.

9. Postpartum Management:

• Readjustment of Anticonvulsant Dosage: Reduce to pre-pregnancy levels by 4–6 weeks postpartum.

10. Contraception:

• Avoid steroidal contraceptives due to hepatic microsomal enzyme induction.

11. Risk to Infant:

• The risk of having epilepsy in an infant born to a mother with a seizure disorder is four times higher compared to infants born to mothers without a seizure disorder.

Complications Associated with Epilepsy

1. Trauma: During seizures, injuries such as tongue biting and head or limb injuries can occur.
2. Status Epilepticus: A seizure lasting more than 30 minutes or a series of seizures without regaining consciousness between them.
3. Sudden Unexpected Death in Epilepsy (SUDEP): An unexplained sudden death in a person with epilepsy.

ASTHMA IN PREGNANCY

Asthma is a chronic respiratory disorder characterized by recurrent attacks of wheezing and difficulty in breathing due to reversible narrowing of the airways. Asthma flare-ups during pregnancy can cause decreased oxygen in blood, which means less oxygen reaches the baby. This put the baby at higher risk for premature birth, low birth weight and poor growth.

Causes

The exact cause of asthma is unknown, but several predisposing factors contribute to its onset. These factors include:

Predisposing Factors

1. Heredity: Asthma often runs in families, suggesting a genetic predisposition.
2. Infections: Respiratory infections, such as the common cold, can trigger asthma attacks.
3. Psychological Factors: Emotions like fear, anger, and nervousness can lead to the release of histamines, precipitating an asthma attack.
4. Allergies: Common allergens include:

• Foods
• Pollen
• Dust
• Weather changes
• Fungi
• Spores
• Feathers
• Drugs (e.g., aspirin)

Respiratory Changes During Pregnancy

Anatomical Changes

• Upper Respiratory Tract: Increased mucosal hyperemia, edema, and glandular hyperactivity.
• Thorax and Diaphragm:

• • Subcostal Angle: Increases from 68 to 103 degrees in the first trimester.

  • Diaphragm: Rises by up to 4 cm.

Hormonal Effects on the Respiratory System

• Oestrogen: Likely responsible for tissue edema, capillary congestion, and hyperplasia of mucous glands.
• Progesterone: Contributes to improved asthma control through increased minute ventilation, smooth muscle relaxation, or cAMP-induced bronchodilation. However, it may also worsen asthma by altering beta2-adrenoceptor responsiveness and airway inflammation. Progesterone acts as a partial glucocorticoid agonist, suppressing histamine release from basophils.
• Cortisol: Maternal plasma cortisol levels increase, which may improve asthma control and reduce steroid requirements, though the effects are variable.
• Prostaglandins: Amniotic fluid contains various prostaglandins (PGE2, PGD2, PGF2-alpha). PGE2 is a bronchodilator, while others are bronchoconstrictors. The relationship between increased PGF2-alpha levels and asthma exacerbations is not well established.

Signs & Symptoms

History Taking

• Family History: A family history of asthma, allergies, or frequent upper respiratory infections, particularly in the mother, increases the risk.
• Personal History: A prior history of asthma, eczema, or hay fever can indicate a predisposition to asthma during pregnancy.
• Onset: Sudden onset of wheezing, shortness of breath, and chest tightness, especially if it\’s a new experience for the mother.
• Triggers: Identifying known triggers such as dust, pollen, smoke, exercise, or certain medications can help manage the condition.
• Severity: Determining the severity of past asthma episodes, including hospitalizations or emergency room visits, can inform treatment decisions.
• Medications: Knowing current asthma medications, including inhalers and oral medications, and adherence to the treatment plan.

Examination

• Cough: May be productive (with phlegm) or dry, often worse at night or during exercise.
• Dyspnea: Difficulty breathing, shortness of breath, and feeling like you can\’t get enough air.
• Chest Tightness: A constricting or squeezing sensation in the chest.
• Wheezing: High-pitched whistling sound during exhalation, sometimes heard during inhalation.
• Rhonchi: Rattling or rumbling sounds in the chest, often indicating airway inflammation or mucus buildup.
• Cyanosis: Bluish discoloration of the skin, lips, or fingernails, signifying low blood oxygen levels.
• Accessory Muscle Use: Overuse of respiratory muscles in the neck, abdomen, or chest, to aid breathing, indicating significant respiratory effort.
• Prolonged Expiration: Exhalation takes longer than inhalation due to narrowed airways.
• Tachypnea: Rapid breathing rate.
• Retractions: Pulling in of the chest wall or neck muscles during inhalation, a sign of respiratory distress.
• Agitation: Restlessness, anxiety, or confusion, often associated with low blood oxygen levels.
• Pulsus Paradoxus: A significant drop in blood pressure during inhalation, indicating severe airway narrowing.

Warning signs of Asthma Attack

History Findings:

• Cough: A persistent cough, especially if it\’s dry and hacking, can be an early sign.
• Shortness of breath: Difficulty catching your breath, feeling like you can\’t get enough air.
• Chest tightness: A constricting feeling in the chest, making it difficult to breathe deeply.
• Noisy breathing: Wheezing (high-pitched whistling sound), or rhonchi (rattling or rumbling sounds) during breathing.
• Nocturnal awakenings: Waking up at night due to difficulty breathing.
• Exacerbations possibly provoked by nonspecific stimuli: Triggers like dust, pollen, smoke, or exercise causing worsening symptoms.
• Personal or family history of other atopic diseases: Having a history of allergies, eczema, or hay fever can increase the risk of asthma.

General Physical Examination:

• Tachypnea: Rapid breathing.
• Retraction (sternomastoid, abdominal, pectoralis muscles): Muscles in the neck, abdomen, or chest pulling inwards during inhalation as the body tries to get more air.
• Agitation: Restlessness, anxiety, or confusion, often a sign of hypoxia (low oxygen levels).
• Pulsus paradoxus ( > 20 mm Hg): A significant drop in blood pressure during inhalation.

Pulmonary Findings:

• Diffuse wheezes: Long, high-pitched whistling sounds on exhalation and sometimes inhalation.
• Diffuse rhonchi: Short, high- or low-pitched rattling sounds during inhalation and/or exhalation.
• Bronchovesicular sounds: Abnormal lung sounds indicating airway narrowing.

Signs of Fatigue and Near-Respiratory Arrest:

• Alteration in the level of consciousness: Lethargy, drowsiness, or confusion, indicating respiratory acidosis and fatigue.
• Abdominal breathing: Using the abdominal muscles to help with breathing, a sign of respiratory distress.
• Inability to speak in complete sentences: Speaking in short, choppy phrases due to shortness of breath.

Signs of Complicated Asthma:

• Equality of breath sounds: Checking for equal air movement on both sides of the chest (signs of pneumonia, mucous plugs, or barotrauma).
• A silent chest: The absence of wheezing in someone experiencing respiratory distress can be more worrisome than the presence of wheezing.
• Jugular venous distension: Swelling of the neck veins, suggesting increased pressure in the chest cavity (possible pneumothorax).
• Hypotension and tachycardia: Low blood pressure and fast heart rate, suggesting possible tension pneumothorax.
• Fever: May indicate an upper or lower respiratory infection, which can worsen asthma symptoms.

Management of Asthma in Pregnancy

Aims of Management

• Control symptoms, including nocturnal symptoms.
• Prevent acute exacerbations.
• Ensure no limitations on activities.
• Maintain (near) normal pulmonary function.
• Protect the mother and fetus from adverse effects.

Preventive Measures

When the patient is not experiencing an attack, prevention is very important. The following advice is given:

1. Education: Inform the patient about asthma and identify potential triggers.
2. Avoidance of Triggers: Avoid substances that trigger attacks (varies by individual).
3. Warm Clothing: Use warm clothes, such as scarves, in cold weather.
4. Emotional Control: Learn to manage emotions to prevent attacks.
5. Deep Breathing Exercises: Practice exercises to ensure full lung expansion.
6. Medication: Always have a supply of prescribed drugs (e.g., inhalers) according to the prescriptions.

Emergency Management

If the patient is experiencing an attack, treat it as an emergency:

1. Admission: Quickly admit the patient in an upright position and administer oxygen if available.
2. Reassurance: Reassure the patient and relatives to reduce anxiety, which can exacerbate the condition.
3. Ventilation: Ensure proper ventilation and inform the doctor.
4. Medical Treatment:
5. Bronchodilators: Administer intravenous Aminophylline (250-500mg every 8 hours, given slowly over 20 minutes). Nebulized salbutamol (4mg every 8 hours), which may later be replaced with ordinary inhalers.

• Corticosteroids: Hydrocortisone (100mg intravenously every 8 hours), later changed to oral prednisolone.
• Antihistamines: Piriton or Phenergan to reduce allergic reactions and congestion.
• Antibiotics: Crystalline penicillin (2ml every 6 hours) or Ampicillin (500mg every 6 hours) to prevent or treat respiratory infections.
• Intravenous Fluids: Administer dextrose 5% to prevent dehydration and provide energy.

Quick Relief for All Patients

• Short-acting bronchodilator: 2-4 puffs of short-acting inhaled beta-agonist(Such as Salbutamol) as needed for symptoms. Intensity of treatment depends on the severity of exacerbation; up to 3 times at 20-minute intervals or a single nebulizer treatment as needed. A course of systemic corticosteroids may be needed. Use of short-acting inhaled beta-agonist more than 2 times a week in intermittent asthma (daily, or increasing use in persistent asthma) may indicate the need to initiate or increase long-term control therapy.

Step Ladder Management

1. Step 1: Occasional use of inhaled short-acting beta2-adrenoceptor agonist bronchodilators.
2. Step 2: Introduction of regular preventer therapy, preferably inhaled corticosteroids (ICS).
3. Step 3: Add-on therapy with long-acting beta2-agonists (LABAs), such as salmeterol and formoterol.
4. Step 4: Poor control with Step 3: Addition of a fourth drug, such as leukotriene receptor antagonists or theophyllines.
5. Step 5: Continuous or frequent use of oral steroids.

Non-Pharmacological Management

Patient Education

• Explain that it is safer for pregnant women with asthma to take asthma medications than to have ongoing symptoms or exacerbations.
• Reassure that safe and adequate asthma treatment is possible during pregnancy and that good asthma control minimizes the risk of complications.

Smoking Cessation

• Smoking increases the risk of asthma exacerbations, bronchitis, or sinusitis, and necessitates an increased need for medication.
• Associated with adverse pregnancy outcomes, including spontaneous pregnancy loss, placental abruption, preterm premature rupture of membranes (PPROM), placenta previa, preterm labor and delivery, low birth weight, and ectopic pregnancy.

Control of Environmental Triggers

• Reduce the need for pharmacologic intervention by avoiding exposure to allergens and nonspecific airway irritants like tobacco smoke, dust, and environmental pollutants.
• Particular allergens of concern include dander from pets and antigens from household dust mites.

Nursing Care

Bed Rest: Complete bed rest is essential, with assistance provided for all activities due to dyspnea.

• Maternal Positioning: Pregnant patients with acute asthma should rest in a seated or lateral position to avoid aortocaval compression by the gravid uterus, particularly in the third trimester.
• Hydration: Intravenous fluids are not necessary unless the patient cannot maintain oral hydration.
• Supplemental Oxygen: Initially 3 to 4 L/min by nasal cannula, adjusting to maintain a PaO2 of at least 70 mmHg and/or oxygen saturation of 95% or greater.

• Observation: Monitor fetal condition and mother’s response to treatment closely.

Management Of Acute Attacks Of Asthma (Asthma Exacerbation) In Pregnancy

• Avoidance of asthma triggers (allergens, irritant) to minimize airway inflammation and hyper-responsiveness.
• Oxygen inhalation with mask to maintain Oxygen saturation > 95% (pulse oximeter).
• High dose albuterol by nebulization every 20 minutes and inhaled ipratropium bromide and systemic corticosteroid. 
• Repeat assessment of symptom, physical examination and Oxygen  saturation to be done.
• Corticosteroids: Intravenous hydrocortisone 200 mg stat and to be repeated after 4 hours. Because of long onset of action, corticosteroids should be given along with β2-agonists. 
• Mechanical ventilation is needed for status asthmaticus to avoid hypoxemia and carbon dioxide retention.

Pharmacotherapy in Exacerbations

• Agents: The recommended agents include inhaled short-acting beta-agonists e.g Albuterol (ProAir, Ventolin), levalbuterol (Xopenex), terbutaline (Brethine). These are often given via nebulizer or metered-dose inhaler (MDI), inhaled anticholinergic agents e.g Ipratropium bromide (Atrovent), oral or intravenous glucocorticoids Oral prednisone or methylprednisolone (Solu-Medrol).
• Systemic Glucocorticoids: Benefits outweigh risks in preventing life-threatening asthma exacerbations e.g Dexamethasone.
• Ipratropium: Used to treat severe acute asthma exacerbations.
• Intravenous Magnesium Sulfate: Magnesium sulfate can be used in severe, life-threatening asthma exacerbations, especially in those who haven\’t responded well to other treatments. It has bronchodilating and anti-inflammatory effects.

Asthma Management During Labor and Delivery

• Only 10-20% of women develop an exacerbation during labor and delivery.
• Opiate analgesics should be avoided as they are bronchoconstrictor and respiratory depressant. Maternal oxygenation should be adequately maintained. Labetalol should be avoided as it may precipitate asthma.
• Hydrocortisone 100 mg IV 8 hourly during labor and 24 hours postpartum is to be given if the patient had steroids within the previous 4 weeks. Inhaled corticosteroid (fluticasone, budesonide) prevents bronchial hyper-responsiveness to allergens.
• Syntocinon is better than ergometrine because of bronchoconstrictor effect of the latter. PGF2 α should not be used, as it precipitates bronchospasm. PGE1 and PGE2 compounds can be used locally for induction of labour or abortion.
• Epidural anesthesia is preferable to general anesthesia because of risk of atelectasis and subsequent chest infection following the latter. Halothane is better in general anesthesia. However, it produces uterine atony.
• Ketamine is used for induction of general anesthesia as it prevents bronchospasm.
• Oxygen saturation is assessed with pulse oximeter or arterial blood gases.
• Postnatal physiotherapy is maintained and drugs are continued.
• Breastfeeding should be encouraged, as it delays the onset of allergic problems in the child. Drugs used in asthma: Prednisolone, corticosteroids, LABA, LTRA do not contraindicate breast feeding.
• Contraception: Barrier method is the best. For terminal contraception, husband is to be motivated for vasectomy.

Peripartum Care

• Oxytocin: The drug of choice for labor induction and postpartum hemorrhage control.
• Pain Control: Avoid morphine and meperidine; use fentanyl or butorphanol. Epidural anesthesia is preferred; if general anesthesia is needed, use ketamine due to its bronchodilatory effect. Avoid ergot derivatives.
• Monitoring: Monitor blood glucose levels in the baby if high doses of short-acting beta-agonists were used during labor and delivery.

Effects of Asthma on Pregnancy

1. Infections: Increased susceptibility due to lowered resistance.
2. Physiological Changes: Nervous system changes can lead to frequent attacks.
3. Complications:

• Exhaustion, stress, cyanosis, and dyspnea can cause intrauterine hypoxia.
• Rapid pulse, tachypnea, and lowered blood pressure.
• Mental confusion due to reduced oxygen to the brain.
• Placental insufficiency leading to intrauterine growth retardation.

Maternal Risks:

• Hyperemesis (severe nausea and vomiting): Asthma medications, particularly inhaled corticosteroids, can contribute to nausea and vomiting.
• Accidental haemorrhage: Increased risk of bleeding during pregnancy since some asthma features can predispose mother to trauma.
• Respiratory failure: Severe asthma attacks can lead to respiratory failure, requiring mechanical ventilation.
• Pregnancy-induced hypertension (PIH): Asthma may increase the risk of developing PIH, a serious condition characterized by high blood pressure during pregnancy.
• Preterm labour and premature birth: Asthma exacerbations can trigger contractions and lead to early delivery.
• Increased risk of maternal death: Severe asthma complications, particularly respiratory failure, can be life-threatening.

Effects on Labor

• Status Asthmaticus: An attack that does not respond to usual treatment.
• Fetal Asphyxia: Due to constriction of blood vessels in the lungs.
• Maternal Distress: Significant distress and potential obstetric shock.
• Assisted Delivery: Necessary due to the mother’s inability to push effectively.

Effects on the Baby

1. Oligohydramnios (low amniotic fluid levels): Asthma medications can affect the baby\’s fluid balance, potentially leading to low amniotic fluid.
2. Low birth weight (LBW): Premature birth, which is more common in women with asthma, is a major factor contributing to LBW.
3. Premature delivery: Asthma can increase the chances of delivering before the full term of pregnancy.
4. Fetal demise (death): Severe asthma complications, particularly during the third trimester, can lead to fetal distress and death.
5. Meconium staining (indicating fetal distress): Fetal distress can cause the baby to release meconium (first stool) into the amniotic fluid.

Neonatal Risks:

1. Neonatal hypoxemia (low oxygen levels): Premature babies born to mothers with asthma are more likely to experience low oxygen levels at birth.
2. Low newborn assessment scores: Prematurity and low oxygen levels can negatively impact the baby\’s apgar score.
3. Increased perinatal mortality: Premature birth and complications associated with asthma can increase the risk of infant death.

Complications

1. Cardiac Failure: Due to the increased strain on the heart.
2. Respiratory Failure: Severe and untreated attacks can lead to respiratory failure.
3. Poor Lactation: Due to the physical stress and medication.
4. Chronic Bronchitis: Frequent attacks may lead to chronic bronchitis.
5. Atonic Uterus: Resulting in prolonged labor or postpartum hemorrhage.
6. Abortions and Premature Labor: Due to the stress and physical demands of asthma.
7. Neonatal Complications: Various complications can arise due to the mother’s condition.